Bizarre Patents
Neuroimaging as a Marketing Tool
Neuroimaging as a means for validating whether a stimulus such as advertisement, communication, or product evokes a certain mental response such as emotion, preference, or memory, or to predict the consequences of the stimulus on later behavior such as consumption or purchasing.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7288252 | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or ... | 10/30/2007 |
| 7288635 | Antibodies to a testis-specific differentiation-regulatory factor A gene expressed specifically in the testis has been unexpectedly isolated in the course of studies of the expression of a gene encoding an unknown protein that triggers cell death. The isolated gene was a novel gene sequence that had no significant homologue in the... | 10/30/2007 |
| 7288381 | Group 2 allergen specific IgE-Fabs and use thereof The present invention relates to group 2 allergen specific IgE-Fabs and whole Ig molecules as well as use thereof. More precisely, the present invention relates to grass pollen specific IgE-Fabs (Phl p2) and reagents, kits and vaccines comprising these. The inventio... | 10/30/2007 |
| 7288636 | Forms of prostate specific antigens and methods for their detection Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also ... | 10/30/2007 |
| 7288638 | Fully human antibodies against human 4-1BB Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject compris... | 10/30/2007 |
| 7285645 | PRO4356 antibodies The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 10/23/2007 |
| 7285639 | Antibody to telomerase reverse transcriptase The present invention is directed to monoclonal or recombinant antibodies or fragments thereof that bind to human telomerase reverse transcriptase (hTRT) protein. The present invention is also directed to methods of identifying or detecting hTRT polypeptides in biol... | 10/23/2007 |
| 7285644 | Secreted and transmembrane polypeptides and nucleic acids encoding the same The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 10/23/2007 |
| 7285642 | Composition and method for modulating dendritic cell-T cell interaction The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another ma... | 10/23/2007 |
| 7282203 | Use of NOTCH pathway interfering agents for treatment of plasma cell disorders The present invention provides a method for reducing the severity of, or treatment of, plasma cell disorders. The method comprises the step of administering to an individual afflicted with a plasma cell disorder, a composition comprising an antibody directed to the ... | 10/16/2007 |
| 7282205 | Anti-hepatitis A virus antibodies Chimpanzee monoclonal antibodies and antigen binding fragments including a γ1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding ... | 10/16/2007 |
| 7282207 | Reagents and methods useful for detecting diseases of the reproductive tissues This invention relates generally to a multimeric polypeptide complex/antigen which may be utilized in detecting or diagnosing diseases of the uterus such as uterine cancer. Furthermore, the invention relates to methods and kits, for example, which utilize this antig... | 10/16/2007 |
| 7282567 | Monoclonal antibody hPAM4 This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope o... | 10/16/2007 |
| 7282569 | PRO1508 antibodies The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 10/16/2007 |
| 7282570 | Compositions and methods for the treatment of immune related diseases The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. ... | 10/16/2007 |
| 7282568 | Human monoclonal antibodies against interleukin 8 (IL-8) Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human... | 10/16/2007 |
| 7276239 | Recombinant A2-specific TNFα-specific antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 10/02/2007 |
| 7276251 | Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles... | 10/02/2007 |
| 7276588 | Antibody of human mitochondrial voltage dependent anion channel An isolated antibody that binds to a plasminogen kringle 5 receptor, i.e., the human voltage-dependent anion channel, preferably at an epitope between amino acids Tyr224 through Lys255 thereof, is described, along with methods of use thereof. P... | 10/02/2007 |
| 7276586 | Antibodies to a polypeptide encoded by a nucleic acid under-expressed in stomach and lung tumor The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 10/02/2007 |
| 7276585 | Immunoglobulin variants outside the Fc region The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application. ... | 10/02/2007 |
| 7273926 | Antibody to PRO1779 polypeptides The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 09/25/2007 |
| 7273924 | Antibodies to the ED-B domain of fibronectin, their construction and uses A specific binding member is specific for and binds directly to the ED—B oncofoetal domain of fibronectin (FN). ... | 09/25/2007 |
| 7271250 | PRO1757 antibodies The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 09/18/2007 |
| 7271248 | Human receptor proteins; related reagents and methods Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention a... | 09/18/2007 |
| 7271247 | Antibodies to a polypeptide encoded by a nucleic acid differentially expressed in melanoma The present invention is directed to novel antibodies that bind to polypeptides encoded by nucleic acids that are differentially expressed in melanoma tumors. ... | 09/18/2007 |
| 7264805 | Proteins with a high immunoreactivity and a method for the production thereof The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemic... | 09/04/2007 |
| 7265210 | Anti-PRO9821 antibodies Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of the... | 09/04/2007 |
| 7264807 | Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms This invention pertains to a method for treating ulcerative colitis. Specifically, the method comprises orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of an antibody which binds to a tropomyosin isoform assoc... | 09/04/2007 |
| 7264967 | Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding The present invention provides an antibody which specifically recognizes an epitope containing a part of a domain based on a finding that the domain ranging from the 269- to 315-positions of human CD14 represented by SEQ ID NO:1 is a site capable of interacting with... | 09/04/2007 |
| 7264801 | EG-VEGF nucleic acids and polypeptides and method of use The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules co... | 09/04/2007 |
| 7261893 | Neutralizing antibodies against GDF-8 and uses therefor The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagno... | 08/28/2007 |
| 7262062 | Diagnostic for scleroderma As anti-RNA polymerase (RNAP) antibodies are detected with high frequency in patients suffering from cutaneous scleroderma where skin sclerosis progresses rapidly, supervenes scleroderma renal crisis at a high rate, and associates with clinical entities whose progno... | 08/28/2007 |
| 7261890 | Methods for using canine immunoglobulin variable domains and caninized antibodies The present invention provides canine heavy chain and light chain (both λ and κ) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised of the presently disclosed canine variable domain framework sequence... | 08/28/2007 |
| 7258989 | Carbohydrate deficient transferrin (CDT) -specific antibodies, their preparation and use The present invention relates to antibodies which, in agueous solution, selectively bind to a transferrin-homologous carbohydrate deficient transferrin (CDT) without the latter needing to be bound to a solid phase. CDT is characterized by at least one of the two oli... | 08/21/2007 |
| 7258991 | Antibody to bladder cancer nuclear matrix protein and its use Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also... | 08/21/2007 |
| RE39789 | Tumor therapy Neoplasia is treated by administering to a mammalian host a composition comprising ligands for the NKG2D receptor. In addition, other NKG2D ligands, proteins specific for the neoplastic cells and cytokines may be included to enhance the immune response. The composit... | 08/21/2007 |
| 7259022 | Production of motif-specific and context-independent antibodies using peptide libraries as antigens A method is provided for producing motif-specific, context-independent antibodies which recognize a plurality of peptides or proteins within a genome that contain the same motif. The method includes the step of immunizing a host with a degenerate peptide library ant... | 08/21/2007 |
| 7258985 | Intrabodies with defined framework that is stable in a reducing environment and applications thereof A method for the isolation of CDRs in a defined framework that is stable and soluble in reducing environment is described as well as thus obtainable scFv. Starting from such scFv with defined framework a scFv library can be generated wherein the framework is conserv... | 08/21/2007 |
| 7258986 | Intrabodies with defined framework that is stable in a reducing environment and applications thereof A method for the isolation of CDRs in a defined framework that is stable and soluble in reducing environment is described as well as thus obtainable scFv. Starting from such scFv with defined framework a scFv library can be generated wherein the framework is conserv... | 08/21/2007 |
